Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Myriad Genetics Inc | MYGN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 23.99 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 23.99 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 13.82 - 25.95 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 23.99 | USD |
Myriad Genetics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.16B | 89.87M | - | 753.2M | -263.3M | -2.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Myriad Genetics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MYGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 24.36 | 25.54 | 23.77 | 24.67 | 672,868 | -0.37 | -1.52% |
| 1 Month | 18.15 | 25.95 | 17.90 | 22.71 | 976,965 | 5.84 | 32.18% |
| 3 Months | 22.02 | 25.95 | 17.90 | 21.72 | 756,090 | 1.97 | 8.95% |
| 6 Months | 17.73 | 25.95 | 17.18 | 21.17 | 698,872 | 6.26 | 35.31% |
| 1 Year | 21.97 | 25.95 | 13.82 | 20.04 | 634,716 | 2.02 | 9.19% |
| 3 Years | 27.97 | 36.9547 | 13.82 | 22.55 | 590,195 | -3.98 | -14.23% |
| 5 Years | 24.60 | 48.40 | 9.24 | 22.32 | 729,953 | -0.61 | -2.48% |
Myriad Genetics Description
| Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies. |
